ID   Ca9-22
AC   CVCL_1102
SY   CA9-22; Ca 9-22; CA922; Ca922
DR   BTO; BTO:0005204
DR   CLO; CLO_0051380
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN01821673
DR   CCLE; CA922_UPPER_AERODIGESTIVE_TRACT
DR   Cell_Model_Passport; SIDM00489
DR   CGH-DB; 355-2
DR   ChEMBL-Cells; CHEMBL3308714
DR   ChEMBL-Targets; CHEMBL1075404
DR   Cosmic; 753538
DR   Cosmic; 930339
DR   Cosmic; 932155
DR   Cosmic; 1042302
DR   Cosmic; 1046026
DR   Cosmic; 1118791
DR   Cosmic; 1120700
DR   Cosmic; 1123036
DR   Cosmic; 1140783
DR   Cosmic; 1219867
DR   Cosmic; 1317411
DR   Cosmic; 2266786
DR   Cosmic; 2546832
DR   Cosmic-CLP; 753538
DR   DepMap; ACH-002043
DR   GDSC; 753538
DR   GEO; GSM301576
DR   GEO; GSM827235
DR   GEO; GSM850380
DR   GEO; GSM1669642
DR   IARC_TP53; 1095
DR   JCRB; JCRB0625
DR   LINCS_HMS; 50007
DR   LINCS_LDP; LCL-2033
DR   PharmacoDB; Ca922_160_2019
DR   RCB; RCB1976
DR   TKG; TKG 0485
DR   Wikidata; Q54808305
RX   DOI=10.5794/jjoms.23.619;
RX   PubMed=275414;
RX   PubMed=1570156;
RX   PubMed=2228902;
RX   PubMed=4549822;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=10741724;
RX   PubMed=12738951;
RX   PubMed=17052259;
RX   PubMed=17325662;
RX   PubMed=17599052;
RX   PubMed=18097548;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21868764;
RX   PubMed=27397505;
RX   PubMed=29156801;
RX   PubMed=30894373;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Partially contaminated. Some stocks of Ca9-22 are contaminated with MSK-922 (PubMed=21868764).
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00437.
CC   HLA typing: A*02:07,24:02; B*35,46:01; C*01:02,14:02 (PubMed=9023415).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: TP53 p.Arg248Trp (c.742C>T) (PubMed=1570156; PubMed=10741724).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.96%; Native American=0%; East Asian, North=79.73%; East Asian, South=18.82%; South Asian=0%; European, North=0%; European, South=0.49% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; JCRB; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9,10
ST   D5S818: 12
ST   D7S820: 11,13
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C129857; Gingival squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-19; Version: 28
//
RX   DOI=10.5794/jjoms.23.619;
RA   Horikoshi M., Katsumura A., Fujibayashi T., Soda T., Itoh H.;
RT   "Lymphocyte mediated cytotoxicity to oral squamous cell carcinoma cell
RT   line (Ca 9-22).";
RL   Nihon Koku Geka Gakkai Zasshi 23:619-625(1977).
//
RX   PubMed=275414; DOI=10.5357/koubyou.45.20;
RA   Kimura Y.;
RT   "Studies on lactate dehydrogenase isoenzymes in a cell line (Ca 9-22)
RT   derived from carcinoma of the gingiva.";
RL   Kokubyo Gakkai Zasshi 45:20-35(1978).
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
//
RX   PubMed=4549822; DOI=10.5794/jjoms.20.100;
RA   Horikoshi M., Kimura Y., Nagura H., Ono T., Ito H.;
RT   "A new human cell line derived from human carcinoma of the gingiva. I.
RT   Its establishment and morphological studies.";
RL   Nihon Koku Geka Gakkai Zasshi 20:100-106(1974).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=10741724;
RA   Eura M., Chikamatsu K., Katsura F., Obata A., Sobao Y., Takiguchi M.,
RA   Song Y., Appella E., Whiteside T.L., DeLeo A.B.;
RT   "A wild-type sequence p53 peptide presented by HLA-A24 induces
RT   cytotoxic T lymphocytes that recognize squamous cell carcinomas of the
RT   head and neck.";
RL   Clin. Cancer Res. 6:979-986(2000).
//
RX   PubMed=12738951; DOI=10.1067/moe.2003.36;
RA   Sugiyama M., Bhawal U.K., Dohmen T., Ono S., Miyauchi M., Ishikawa T.;
RT   "Detection of human papillomavirus-16 and HPV-18 DNA in normal,
RT   dysplastic, and malignant oral epithelium.";
RL   Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:594-600(2003).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x;
RA   Kozaki K.-I., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17325662; DOI=10.1038/sj.onc.1210330;
RA   Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-I., Nose M., Miki T.,
RA   Hamakawa H.;
RT   "Identification of homozygous deletions of tumor suppressor gene FAT
RT   in oral cancer using CGH-array.";
RL   Oncogene 26:5300-5308(2007).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-I., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S., Shen L., Sambandam V., Rao X., Xi Y.,
RA   Li L., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J.,
RA   Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//